{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:32:33Z","timestamp":1776760353898,"version":"3.51.2"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":2653,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1038\/ki.2008.231","type":"journal-article","created":{"date-parts":[[2008,6,4]],"date-time":"2008-06-04T12:39:38Z","timestamp":1212583178000},"page":"571-576","source":"Crossref","is-referenced-by-count":54,"title":["Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease"],"prefix":"10.1016","volume":"74","author":[{"given":"Linda F.","family":"Fried","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2008.231_bb0010","first-page":"S29","article-title":"Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis","volume":"31","author":"Diamond","year":"1991","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2008.231_bb0015","first-page":"S16","article-title":"Lipid abnormalities in chronic renal insufficiency","volume":"31","author":"Attman","year":"1991","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2008.231_bb0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/11.1.63","article-title":"Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure","volume":"11","author":"Attman","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.231_bb0025","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1093\/ndt\/13.11.2833","article-title":"The compositional abnormalities of lipoproteins in diabetic renal failure","volume":"13","author":"Attman","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.231_bb0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1055\/s-0038-1650639","article-title":"Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure","volume":"76","author":"Holvoet","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1038\/ki.2008.231_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpneph0101","article-title":"Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?","volume":"2","author":"Kwan","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1038\/ki.2008.231_bb0040","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/ki.1987.151","article-title":"Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients","volume":"31","author":"Kaysen","year":"1987","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0045","first-page":"144","article-title":"Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits. II. Long term studies","volume":"24","author":"Wellmann","year":"1971","journal-title":"Lab Invest"},{"key":"10.1038\/ki.2008.231_bb0050","first-page":"204","article-title":"Dietary induced glomerulosclerosis in the guinea pig","volume":"83","author":"French","year":"1967","journal-title":"Arch Pathol"},{"key":"10.1038\/ki.2008.231_bb0055","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/ki.1990.62","article-title":"Renal injury of diet-induced hypercholesterolemia in rats","volume":"37","author":"Kasiske","year":"1990","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0060","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1681\/ASN.V114669","article-title":"Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats","volume":"11","author":"Joles","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.231_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0272-6386(86)80055-5","article-title":"Nephropathy of familial lecithin-cholesterol acyltransferase deficiency: report of a case","volume":"7","author":"Ohta","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.231_bb0070","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2337\/diacare.16.10.1376","article-title":"Predictors of microalbuminuria in individuals with IDDM. Pittsburgh epidemiology of diabetes complications study","volume":"16","author":"Coonrod","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2008.231_bb0075","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/ndt\/12.9.1908","article-title":"Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency","volume":"12","author":"Samuelsson","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.231_bb0080","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archinte.158.9.998","article-title":"Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia","volume":"158","author":"Ravid","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1038\/ki.2008.231_bb0085","first-page":"S125","article-title":"Hypercholesterolemia\u2014a determinant of renal function loss and deaths in IDDM patients with nephropathy","volume":"45","author":"Krolewski","year":"1994","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2008.231_bb0090","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.2337\/diacare.26.5.1402","article-title":"Analysis of metabolic parameters as predictors of risk in the RENAAL study","volume":"26","author":"Appel","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2008.231_bb0095","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ki.1988.51","article-title":"Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats","volume":"33","author":"Kasiske","year":"1988","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1159\/000089905","article-title":"Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy","volume":"25","author":"Li","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2008.231_bb0105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00125-003-1099-3","article-title":"Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model","volume":"46","author":"Ota","year":"2003","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2008.231_bb0110","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1046\/j.1523-1755.1999.07109.x","article-title":"Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy","volume":"71","author":"Jandeleit-Dahm","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2008.231_bb0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.ki.5000086","article-title":"Simvastatin protection against acute immune-mediated glomerulonephritis in mice","volume":"69","author":"Christensen","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0120","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","article-title":"The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study","volume":"57","author":"Athyros","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1038\/ki.2008.231_bb0125","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","article-title":"Statins for improving renal outcomes: a meta-analysis","volume":"17","author":"Sandhu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.231_bb0130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.231_bb0135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7326\/0003-4819-145-2-200607180-00009","article-title":"Meta-analysis: the effect of statins on albuminuria","volume":"145","author":"Douglas","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2008.231_bb0140","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ASN.0000068461.45784.2F","article-title":"Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease","volume":"14","author":"Tonelli","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.231_bb0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.0000022805.11288.7F","article-title":"Effect of pravastatin on proteinuria in patients with well-controlled hypertension","volume":"40","author":"Lee","year":"2002","journal-title":"Hypertension"},{"key":"10.1038\/ki.2008.231_bb0150","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","article-title":"A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease","volume":"41","author":"Bianchi","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.231_bb0155","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1093\/ndt\/gfl244","article-title":"The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study","volume":"21","author":"Atthobari","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.231_bb0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.ki.5001515","article-title":"Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes","volume":"70","author":"Tonolo","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0165","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1523-1755.2005.00457.x","article-title":"Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers","volume":"68","author":"Lee","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0170","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/ki.1991.108","article-title":"Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro","volume":"39","author":"Coritsidis","year":"1991","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0175","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/ki.1992.177","article-title":"Interactions of LDL and modified LDL with mesangial cells and matrix","volume":"41","author":"Gupta","year":"1992","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0180","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1681\/ASN.V541081","article-title":"Preferential uptake of intermediate-density lipoproteins from nephrotic patients by human mesangial and liver cells","volume":"5","author":"Kramer-Guth","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.231_bb0185","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.1993.35","article-title":"LDL stimulates mesangial fibronectin production and chemoattractant expression","volume":"43","author":"Rovin","year":"1993","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0167-5273(02)00195-X","article-title":"Beyond lipid lowering: the role of statins in vascular protection","volume":"86","author":"Liao","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1038\/ki.2008.231_bb0195","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0216421","article-title":"Isoprenoids as mediators of the biological effects of statins","volume":"110","author":"Liao","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2008.231_bb0200","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1046\/j.1523-1755.2000.07714.x","article-title":"Effect of lovastatin on small GTP binding proteins and on TGF-beta1 and fibronectin expression","volume":"77","author":"Kim","year":"2000","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2008.231_bb0205","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/01.RES.0000196564.18314.23","article-title":"Rho GTPases, statins, and nitric oxide","volume":"97","author":"Rikitake","year":"2005","journal-title":"Circ Res"},{"key":"10.1038\/ki.2008.231_bb0210","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00125-007-0597-0","article-title":"A novel mechanism of action for statins against diabetes-induced oxidative stress","volume":"50","author":"Vecchione","year":"2007","journal-title":"Diabetologia"},{"key":"10.1038\/ki.2008.231_bb0215","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ejphar.2007.04.011","article-title":"The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats","volume":"568","author":"Gojo","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1038\/ki.2008.231_bb0220","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00240-005-0484-4","article-title":"NF-kappaB and chemokine-cytokine expression in renal tubulointerstitium in experimental hyperoxaluria. Role of the renin\u2013angiotensin system","volume":"33","author":"Toblli","year":"2005","journal-title":"Urol Res"},{"key":"10.1038\/ki.2008.231_bb0225","doi-asserted-by":"crossref","first-page":"F995","DOI":"10.1152\/ajprenal.00092.2006","article-title":"HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced \u2018inside-out\u2019 signaling to extracellular matrix by preventing RhoA activation","volume":"291","author":"Xu","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2008.231_bb0230","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00018-005-5298-6","article-title":"Isoprenylated proteins","volume":"63","author":"McTaggart","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1038\/ki.2008.231_bb0235","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1681\/ASN.V9112027","article-title":"Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis","volume":"9","author":"Yoshimura","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.231_bb0240","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1046\/j.1523-1755.1999.07112.x","article-title":"Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury","volume":"71","author":"Hattori","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2008.231_bb0245","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1523-1755.2004.00710.x","article-title":"Differential effects of simvastatin on mesangial cells","volume":"66","author":"Heusinger-Ribeiro","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0250","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/18.2.265","article-title":"HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats","volume":"18","author":"Usui","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.231_bb0255","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/sj.ki.5000410","article-title":"The podocyte's response to injury: role in proteinuria and glomerulosclerosis","volume":"69","author":"Shankland","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0260","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.ki.5002222","article-title":"The spectrum of podocytopathies: a unifying view of glomerular diseases","volume":"71","author":"Wiggins","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.231_bb0265","first-page":"143A","article-title":"Rosuvastatin protects against podocyte apoptosis in vitro [Abstract]","volume":"18","author":"Cormack-Aboud","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.231_bb0270","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1681\/ASN.2005050571","article-title":"Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling","volume":"17","author":"Shibata","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.231_bb0275","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ndt\/17.5.798","article-title":"Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis","volume":"17","author":"Nakamura","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.231_bb0280","unstructured":"FDA. FDA Advisory Committee Briefing Document NDA 21-366 for the use of Crestor"},{"key":"10.1038\/ki.2008.231_bb0285","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1097\/01.ASN.0000136778.32499.05","article-title":"Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells","volume":"15","author":"Verhulst","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.231_bb0290","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000077704","article-title":"Rosuvastatin-induced arrest in progression of renal disease","volume":"102","author":"Vidt","year":"2004","journal-title":"Cardiology"},{"key":"10.1038\/ki.2008.231_bb0295","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000100908","article-title":"Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program","volume":"107","author":"Shepherd","year":"2007","journal-title":"Cardiology"},{"key":"10.1038\/ki.2008.231_bb0300","doi-asserted-by":"crossref","first-page":"82C","DOI":"10.1016\/j.amjcard.2005.12.015","article-title":"An assessment of statin safety by nephrologists","volume":"97","author":"Kasiske","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1038\/ki.2008.231_bb0305","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381553370X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381553370X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T15:44:50Z","timestamp":1631375090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381553370X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S008525381553370X"],"URL":"https:\/\/doi.org\/10.1038\/ki.2008.231","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}